- Home
- MRT vs RAPT Comparison
MRT vs RAPT Comparison
Compare MRT & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRT
- RAPT
- Stock Information
- Founded
- MRT 2018
- RAPT 2015
- Country
- MRT Turkey
- RAPT United States
- Employees
- MRT N/A
- RAPT N/A
- Industry
- MRT Rental/Leasing Companies
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- MRT Consumer Discretionary
- RAPT Health Care
- Exchange
- MRT Nasdaq
- RAPT Nasdaq
- Market Cap
- MRT 228.0M
- RAPT 194.2M
- IPO Year
- MRT N/A
- RAPT 2019
- Fundamental
- Price
- MRT $2.52
- RAPT $11.32
- Analyst Decision
- MRT Strong Buy
- RAPT Buy
- Analyst Count
- MRT 2
- RAPT 5
- Target Price
- MRT $6.00
- RAPT $33.60
- AVG Volume (30 Days)
- MRT 146.1K
- RAPT 103.2K
- Earning Date
- MRT 01-01-0001
- RAPT 08-07-2025
- Dividend Yield
- MRT N/A
- RAPT N/A
- EPS Growth
- MRT N/A
- RAPT N/A
- EPS
- MRT N/A
- RAPT N/A
- Revenue
- MRT $18,659,655.00
- RAPT N/A
- Revenue This Year
- MRT $83.89
- RAPT N/A
- Revenue Next Year
- MRT $115.32
- RAPT N/A
- P/E Ratio
- MRT N/A
- RAPT N/A
- Revenue Growth
- MRT N/A
- RAPT N/A
- 52 Week Low
- MRT $1.77
- RAPT $5.67
- 52 Week High
- MRT $3.89
- RAPT $26.56
- Technical
- Relative Strength Index (RSI)
- MRT 48.24
- RAPT 54.68
- Support Level
- MRT $2.37
- RAPT $10.06
- Resistance Level
- MRT $2.58
- RAPT $12.25
- Average True Range (ATR)
- MRT 0.11
- RAPT 1.02
- MACD
- MRT 0.02
- RAPT -0.05
- Stochastic Oscillator
- MRT 60.70
- RAPT 73.29
About MRT Marti Technologies Inc.
Marti Technologies Inc is a mobility app, offering multiple transportation services to its riders. Marti operates a ride-hailing service that matches riders with car, motorcycle, and taxi drivers, and operates a large fleet of rental e-mopeds, e-bikes, and e-scooters. All of Marti's offerings are serviced by proprietary software systems and IoT infrastructure.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.